Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP060
MIFTS: 54

Hyperinsulinism

Categories: Endocrine diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hyperinsulinism

About this section

MalaCards integrated aliases for Hyperinsulinism:

Name: Hyperinsulinism 12 54 43 15 71
Hyperinsulinemia 12 29 54 6 15

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2018
MeSH 43 D006946
SNOMED-CT 67 83469008
ICD10 32 E16.1
UMLS 71 C0020459
Sources

Summaries for Hyperinsulinism

About this section
MalaCards based summary : Hyperinsulinism, also known as hyperinsulinemia, is related to hyperinsulinemic hypoglycemia, familial, 2 and hyperinsulinemic hypoglycemia, familial, 6. An important gene associated with Hyperinsulinism is HNF4A (Hepatocyte Nuclear Factor 4 Alpha), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and Aldosterone synthesis and secretion. The drugs Curcumin and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and skeletal muscle, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hyperinsulinism refers to an above normal level of insulin in the blood of a person or animal. Normal... more...

Sources

Related Diseases for Hyperinsulinism

About this section

Diseases related to Hyperinsulinism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 597)
# Related Disease Score Top Affiliating Genes
1 hyperinsulinemic hypoglycemia, familial, 2 34.6 SST KCNJ11 INS HNF4A ABCC8
2 hyperinsulinemic hypoglycemia, familial, 6 34.4 UCP2 SLC16A1 HADH GLUD1 GCK ABCC8
3 hyperinsulinemic hypoglycemia, familial, 7 34.0 UCP2 SLC16A1 KCNJ11 HADH GLUD1 GCK
4 3-hydroxyacyl-coa dehydrogenase deficiency 33.5 HADH GLUD1 GCK
5 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 33.1 INSR INS IGFBP3 IGF1
6 insulinoma 31.9 UCP2 SST INS GCK ABCC8
7 hyperinsulinemic hypoglycemia 31.6 SST SLC16A1 KCNJ11 INSR INS HNF4A
8 hypoglycemia 31.6 SST SLC16A1 KCNJ5 KCNJ11 INSR INS
9 fasting hypoglycemia 31.6 INSR IGF1 GLUD1
10 beckwith-wiedemann syndrome 31.5 KCNJ11 INS IGF1 ABCC8
11 hyperandrogenism 31.3 SHBG INSR INS IGFBP3 IGFBP1 IGF1
12 asphyxia neonatorum 31.2 SLC16A1 KCNJ11 INS HADH ABCC8
13 acute insulin response 31.2 UCP2 KCNJ5 KCNJ11 INS ABCC8
14 monogenic diabetes 31.2 KCNJ11 INS HNF4A GCK ABCC8
15 hypothalamic obesity 31.2 LEP INS IGF1
16 munchausen by proxy 31.2 KCNJ11 GCK ABCC8
17 islet cell tumor 31.1 SST INS IGF1
18 hypertriglyceridemia, familial 31.1 SERPINE1 INS APOB
19 polycystic ovary syndrome 31.1 SHBG LEP INSR INS IGFBP3 IGFBP1
20 maturity-onset diabetes of the young 31.0 UCP2 SST LEP KCNJ11 INS HNF4A
21 hyperproinsulinemia 31.0 SHBG INS IGFBP1
22 acanthosis nigricans 31.0 SHBG LEP INSR INS IGF1
23 non-alcoholic fatty liver disease 31.0 UCP2 SERPINE1 LEP INSR INS APOB
24 non-alcoholic steatohepatitis 30.9 UCP2 SERPINE1 INS IGF1 HNF4A GHRL
25 donohue syndrome 30.9 INSR INS IGFBP3 IGF1 GCK
26 narcolepsy 30.9 SST LEP IGFBP3 GHRL
27 diabetes mellitus, permanent neonatal 4 30.9 KCNJ11 INS GCK ABCC8
28 familial hyperlipidemia 30.9 SERPINE1 LEP INS APOB
29 hypopituitarism 30.8 SHBG LEP INS IGFBP3 IGF1
30 neonatal diabetes mellitus 30.8 KCNJ5 KCNJ11 INS HNF4A GCK ABCC8
31 gestational diabetes 30.8 SHBG LEP KCNJ11 INSR INS IGFBP1
32 hypogonadism 30.7 SHBG LEP INS IGF1
33 atherosclerosis susceptibility 30.7 SERPINE1 LEP INS APOB
34 arteriosclerosis 30.7 SHBG SERPINE1 INS GHRL APOB
35 cerebral palsy 30.7 SERPINE1 LEP IGFBP3 IGF1
36 lipid metabolism disorder 30.7 SHBG SERPINE1 LEP INSR INS HNF4A
37 peptic ulcer disease 30.7 SST INS GHRL
38 ovarian disease 30.7 SHBG SERPINE1 LEP INSR INS IGFBP1
39 leptin deficiency or dysfunction 30.7 LEP INS IGF1 GHRL
40 fetal macrosomia 30.7 LEP INSR INS IGFBP3 IGF1 APOB
41 turner syndrome 30.6 SHBG LEP INS IGFBP3 IGFBP1 IGF1
42 fatty liver disease 30.6 UCP2 LEP INSR INS APOB
43 amenorrhea 30.6 SHBG LEP INS IGF1 GHRL
44 prediabetes syndrome 30.6 LEP INS IGF1 APOB
45 arteries, anomalies of 30.6 SERPINE1 LEP INS APOB
46 diabetic neuropathy 30.6 UCP2 LEP INS
47 diabetes mellitus, permanent neonatal 1 30.6 KCNJ11 INS GCK ABCC8
48 hyperuricemia 30.6 LEP INS APOB
49 fetal erythroblastosis 30.6 HADH GLUD1
50 maturity-onset diabetes of the young, type 2 30.6 KCNJ11 INS HNF4A GCK ABCC8

Graphical network of the top 20 diseases related to Hyperinsulinism:



Diseases related to Hyperinsulinism
Sources

Symptoms & Phenotypes for Hyperinsulinism

About this section

GenomeRNAi Phenotypes related to Hyperinsulinism according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.02 UCP2
2 Decreased viability GR00221-A-1 10.02 GCK INSR
3 Decreased viability GR00221-A-2 10.02 GCK INSR
4 Decreased viability GR00221-A-3 10.02 GCK INSR
5 Decreased viability GR00221-A-4 10.02 GCK INSR
6 Decreased viability GR00240-S-1 10.02 SST
7 Decreased viability GR00249-S 10.02 GHRL HADH IGFBP3 SERPINE1 UCP2
8 Decreased viability GR00381-A-1 10.02 KCNJ5
9 Decreased viability GR00381-A-3 10.02 KCNJ5
10 Decreased viability GR00386-A-1 10.02 APOB HNF4A SLC16A1
11 Decreased viability GR00402-S-2 10.02 GLUD1 IGFBP3 KCNJ5
12 Reduced mammosphere formation GR00396-S 9.23 ABCC8 GHRL HNF4A IGF1 IGFBP3 KCNJ11

MGI Mouse Phenotypes related to Hyperinsulinism:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 APOB GCK HNF4A IGF1 IGFBP3 INS
2 adipose tissue MP:0005375 10.13 GHRL HADH IGF1 IGFBP3 INS INSR
3 growth/size/body region MP:0005378 10.13 APOB GCK GLUD1 HADH HNF4A IGF1
4 cellular MP:0005384 10.11 APOB GCK HADH HNF4A IGF1 IGFBP1
5 endocrine/exocrine gland MP:0005379 10.1 ABCC8 GCK GHRL GLUD1 HADH IGF1
6 homeostasis/metabolism MP:0005376 10.09 ABCC8 APOB GCK GHRL GLUD1 HADH
7 liver/biliary system MP:0005370 9.7 APOB GCK HNF4A IGFBP1 IGFBP3 INS
8 renal/urinary system MP:0005367 9.28 GCK HADH HNF4A IGF1 INS INSR
Sources

Drugs & Therapeutics for Hyperinsulinism

About this section

Drugs for Hyperinsulinism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
4
parecoxib Approved Phase 4 198470-84-7
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Icodextrin Approved, Investigational Phase 4 337376-15-5
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Zinc Approved, Investigational Phase 4 7440-66-6 32051
9
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
10
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
11
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
12
Drospirenone Approved Phase 4 67392-87-4 68873
13
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
14
Losartan Approved Phase 4 114798-26-4 3961
15
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
16
Caffeine Approved Phase 4 58-08-2 2519
17
Atorvastatin Approved Phase 4 134523-00-5 60823
18
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
19
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21
Chlorzoxazone Approved Phase 4 95-25-0 2733
22
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
23
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
24
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
25
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
26
Pasireotide Approved Phase 4 396091-73-9 9941444
27
tannic acid Approved Phase 4 1401-55-4
28
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
29
Testosterone enanthate Approved Phase 4 315-37-7 9416
30
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
31
Methyltestosterone Approved Phase 4 58-18-4 6010
32
Metformin Approved Phase 4 657-24-9 14219 4091
33
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
34
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
35
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
36
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
37
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
38
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
39
Fenofibrate Approved Phase 4 49562-28-9 3339
40
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
41 Garlic Approved, Nutraceutical Phase 4 8008-99-9
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
43
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
44
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
45
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
46
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
47 Tocotrienol Investigational Phase 4 6829-55-6
48
Cobalamin Experimental Phase 4 13408-78-1 6857388
49
Candesartan Experimental Phase 4 139481-59-7 2541
50
2,4-thiazolidinedione Investigational Phase 4 2295-31-0

Interventional clinical trials:

(show top 50) (show all 348)
# Name Status NCT ID Phase Drugs
1 Treatment With Lanreotide Autogel (Somatostatin Analogue) in Patients With Congenital Hyperinsulinism of Infancy Already Treated With Somatostatin Analog by Pump Unknown status NCT01070758 Phase 4 Lanreotide autogel
2 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
3 To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
4 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
5 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
6 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
7 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
8 Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis Unknown status NCT01228279 Phase 4
9 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
10 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
11 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
12 Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial Completed NCT00679679 Phase 4 Metformin;Placebo
13 Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance Completed NCT00667498 Phase 4 Metformin;Placebo
14 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
15 Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
16 Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial Completed NCT01279512 Phase 4 Metformin;Acarbose
17 Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes Completed NCT00212290 Phase 4 pioglitazone;nateglinide;placebo
18 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
19 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
20 Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors Completed NCT00663377 Phase 4 losartan
21 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
22 Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? Completed NCT00745225 Phase 4 Pioglitazone;placebo comparator
23 Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD) Completed NCT00396435 Phase 4 Neorecormon
24 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
25 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
26 Cardiovascular Effects of Chronic Sildenafil (Viagra) Treatment in Diabetic Subjects With Endothelial Dysfunction. Completed NCT00692237 Phase 4 Sildenafil;Placebo
27 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
28 Changes in Adiposity and Metabolic Measures During Medication Switches to Aripiprazole From Other Atypical Antipsychotics Completed NCT00205660 Phase 4
29 Effects of Type 2 Diabetes on CYP450s Activities; Intersubject Variability in Drug Metabolism. Completed NCT02291666 Phase 4 CRCHUM-MT cocktail
30 The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial Completed NCT02460380 Phase 4 Vitamin D3
31 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
32 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Completed NCT02437084 Phase 4 Atorvastatin
33 Effect of Myo-Inositol- Based Co-treatment on Oocyte Quality in Women With Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
34 Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia Active, not recruiting NCT02032953 Phase 4 Insulin
35 Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Enrolling by invitation NCT03514576 Phase 4 Pasireotide 0.3 MG/ML
36 52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters Not yet recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
37 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
38 Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? Suspended NCT03878459 Phase 4 Pioglitazone 45 mg;Placebo
39 A Randomized, Double Blind, Cross-Over, Placebo-Controlled Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism, of Non Diabetic, Non Hypertensive Subjects With Dysglycemia and Abdominal Obesity."ARAMIA" Terminated NCT00319202 Phase 4 Candesartan;Placebo
40 Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
41 Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) Terminated NCT00819910 Phase 4 Rosiglitazone;Placebo (Rosiglitazone);Placebo (Fenofibrate);Fenofibrate
42 Sleep, Metabolic, and Cardiovascular Dysfunction in Polycystic Ovary Syndrome Terminated NCT00203996 Phase 4 depot leuprolide plus estrogen/progestin replacement;pioglitazone
43 A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus Unknown status NCT01245166 Phase 3 Acarbose;Metformin/Acarbose
44 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
45 A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes Completed NCT00856284 Phase 3 Alogliptin;Metformin;Glipizide
46 TART - Troglitazone Atherosclerosis Regression Trial Completed NCT00116545 Phase 2, Phase 3 troglitazone
47 A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer Completed NCT03086005 Phase 3 Metformin
48 Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study Completed NCT00994812 Phase 3 metformin
49 Effect of Administration of Combination Metformine/Inulin Versus Metformine on Patients With Prostate Benign Hyperplasia and Metabolic Syndrome Syndrome Completed NCT02778776 Phase 3 Metformin
50 Active Living and Healthy Diet at the Workplace Completed NCT00123526 Phase 3

Search NIH Clinical Center for Hyperinsulinism

Cochrane evidence based reviews: hyperinsulinism

Sources

Genetic Tests for Hyperinsulinism

About this section

Genetic tests related to Hyperinsulinism:

# Genetic test Affiliating Genes
1 Hyperinsulinemia 29
Sources

Anatomical Context for Hyperinsulinism

About this section

MalaCards organs/tissues related to Hyperinsulinism:

40
Ovary, Liver, Skeletal Muscle, Heart, Pancreas, Endothelial, Testes
Sources

Publications for Hyperinsulinism

About this section

Articles related to Hyperinsulinism:

(show top 50) (show all 14524)
# Title Authors PMID Year
1
Plasma apelin levels in subjects with nonalcoholic fatty liver disease. 61 54
20045153 2010
2
Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. 54 61
20233941 2010
3
Changes in cytokine levels during acute hyperinsulinemia in offspring of type 2 diabetic subjects. 54 61
20031127 2010
4
Adaptations in mitochondrial function parallel, but fail to rescue, the transition to severe hyperglycemia and hyperinsulinemia: a study in Zucker diabetic fatty rats. 54 61
19875988 2010
5
The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. 54 61
20176725 2010
6
A common polymorphism in the promoter of UCP2 is associated with obesity and hyperinsulenemia in northern Indians. 54 61
19908126 2010
7
Hypoadiponectinemia--cause or consequence of human "insulin resistance"? 54 61
20164291 2010
8
Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia. 54 61
20011249 2010
9
NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1. 61 54
19815588 2010
10
Impact of disease-causing SUR1 mutations on the KATP channel subunit interface probed with a rhodamine protection assay. 61 54
19933268 2010
11
On the reversibility of glutamate dehydrogenase and the source of hyperammonemia in the hyperinsulinism/hyperammonemia syndrome. 61 54
19895831 2010
12
Congenital hyperinsulinism due to a compound heterozygous ABCC8 mutation with spontaneous resolution at eight weeks. 54 61
20215776 2010
13
The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. 54 61
19656511 2010
14
Impact of type 1 diabetes and insulin treatment on plasma levels and fractional synthesis rate of retinol-binding protein 4. 61 54
19850685 2009
15
Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. 61 54
19884385 2009
16
Metabolic syndrome and risk of subsequent colorectal cancer. 54 61
19891012 2009
17
Metabolic syndrome racial differences in adolescents. 61 54
19925390 2009
18
Acute hyperinsulinemia differentially regulates interstitial and circulating adiponectin oligomeric pattern in lean and insulin-resistant, obese individuals. 61 54
19820029 2009
19
Molecular biology of K(ATP) channels and implications for health and disease. 61 54
19787700 2009
20
Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach. 61 54
19673658 2009
21
Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. 61 54
19734900 2009
22
Fasting hyperinsulinemia associates with increased sub-clinical inflammation in first-degree relatives normal glucose tolerant women independently of the metabolic syndrome. 54 61
19685554 2009
23
The change in sex hormone binding globulin and the influence by gestational diabetes mellitus in fetal period. 54 61
19557594 2009
24
Low-birth weight children develop lower sex hormone binding globulin and higher dehydroepiandrosterone sulfate levels and aggravate their visceral adiposity and hypoadiponectinemia between six and eight years of age. 61 54
19737922 2009
25
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. 54 61
19752219 2009
26
Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. 61 54
19647774 2009
27
[Obesity and cancer]. 61 54
19524333 2009
28
Alterations in cochlear function during induced acute hyperinsulinemia in an animal model. 54 61
19893948 2009
29
Forkhead transcription factor FoxO1 inhibits insulin- and transforming growth factor-beta-stimulated plasminogen activator inhibitor-1 expression. 54 61
19563779 2009
30
The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile. 61 54
19481769 2009
31
American Diabetes Association--69th Scientific sessions. Hyperinsulinism, insulin resistance and the treatment of diabetes: Part 2. 54 61
19629874 2009
32
Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARalpha. 54 61
19625768 2009
33
Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. 61 54
19531491 2009
34
Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells. 61 54
19520186 2009
35
A novel melanocortin-4 receptor gene mutation in a female patient with severe childhood obesity. 54 61
19214805 2009
36
Insulin resistance and carotid atherosclerosis in patients with type 2 diabetes. 54 61
19147142 2009
37
Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. 54 61
19336674 2009
38
Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene. 54 61
19318379 2009
39
Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index. 61 54
19375766 2009
40
The spectrum of ABCC8 mutations in Norwegian patients with congenital hyperinsulinism of infancy. 61 54
19475716 2009
41
The genetic basis of congenital hyperinsulinism. 61 54
19254908 2009
42
States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. 54 61
18586538 2009
43
[Hyperinsulinism in infancy and childhood: when an insulin level is not always enough]. 54 61
19411227 2009
44
(Pre)diabetes, brain aging, and cognition. 54 61
19135149 2009
45
Acylated ghrelin concentrations are markedly decreased during pregnancy in mothers with and without gestational diabetes: relationship with cholinesterase. 54 61
19240252 2009
46
Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs. 54 61
19179483 2009
47
[Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases]. 54 61
19671283 2009
48
Diagnostic difficulties in glucokinase hyperinsulinism. 54 61
19053014 2009
49
Insulin-like growth factor-binding protein-1: serum levels, promoter polymorphism, and associations with components of the metabolic syndrome in short subjects born small for gestational age. 54 61
19158202 2009
50
Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. 54 61
19100718 2009
Sources

Variations for Hyperinsulinism

About this section

ClinVar genetic disease variations for Hyperinsulinism:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HNF4A NM_175914.4(HNF4A):c.187C>T (p.Arg63Trp)SNV Pathogenic 156152 rs587777732 20:43034835-43034835 20:44406195-44406195
2 KCNJ11 NM_000525.3(KCNJ11):c.185C>G (p.Thr62Arg)SNV Likely pathogenic 373928 rs1057518775 11:17409454-17409454 11:17387907-17387907
3 HNF4A NM_175914.4(HNF4A):c.925C>T (p.Arg309Cys)SNV Conflicting interpretations of pathogenicity 36364 rs193922479 20:43052756-43052756 20:44424116-44424116
Sources

Expression for Hyperinsulinism

About this section
Search GEO for disease gene expression data for Hyperinsulinism.
Sources

Pathways for Hyperinsulinism

About this section

Pathways related to Hyperinsulinism according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.8 SERPINE1 INSR INS IGFBP3 IGF1 GCK
2
Aldosterone synthesis and secretion 36
Show member pathways
 12.79 KCNJ5 KCNJ11 INS GCK ABCC8
3
Relaxin signaling pathway 36
Show member pathways
 12.58 SST KCNJ5 IGFBP3 IGF1 GHRL
4
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.35 LEP INSR INS IGF1 HNF4A
5
Glucose / Energy Metabolism 4
12.29 UCP2 INSR INS IGFBP3 IGFBP1 HNF4A
6
Folate Metabolism 1
Show member pathways
 12.24 SERPINE1 INSR INS APOB
7
Peptide hormone metabolism 65
Show member pathways
 12.15 LEP INS IGF1 GHRL
8
Adipogenesis 1
11.95 SERPINE1 LEP INS IGF1
9
Hepatic ABC Transporters 63
Show member pathways
 11.9 INSR INS HNF4A GCK
10
HIF-1 signaling pathway 36
11.82 SERPINE1 INSR INS IGF1
11
Regulation of beta-cell development 65
Show member pathways
 11.79 INS HNF4A GCK
12
Senescence and Autophagy in Cancer 1
11.78 SERPINE1 INS IGFBP3 IGF1
13
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.71 LEP INS IGFBP3 IGF1
14
Antiarrhythmic Pathway, Pharmacodynamics 60
11.52 KCNJ5 KCNJ11 ABCC8
15
Development_Leptin signaling via PI3K-dependent pathway 22
11.47